Table 2.
Laboratory findings of patients.
| mNGS group (n = 173) | Control group (n = 185) | P | |
|---|---|---|---|
| White blood cell count, x 109/L | 9.41 (0.56–57.27) | 8.44 (1.68-29.47) | 0.035 |
| Percentage of neutrophils, % | 77.9 (9.8–97) | 72.5 (38.5–98.4) | 0.001 |
| Lymphocyte count, x 109/L | 1.07 (0.11–4.14) | 1.28 (0.12–9.51) | 0.005 |
| NLR | 11.18 (0.21–86.47) | 9.05 (0.82–121.20) | 0.001 |
| PLR | 282.82 (9.42–1925.00) | 270.68 (6.00–1103.80) | 0.803 |
| Cre, umol/L | 89 (30–855) | 79 (26–527) | 0.027 |
| PCT, ng/mL | 2.40 (0.01–75.57) | 1.51 (0.01–70.62) | 0.004 |
| CRP, mg/L | 82.65 (0.43–320.04) | 50.14 (0.01–314.69) | 0.001 |
| ESR, mm/h | 63.49 (2–120) | 54.73 (2–120) | 0.081 |
| Ca2+, mmol/L | 2.04 (0.99–2.49) | 2.15 (1.15–3.34) | 0.001 |
| Albumin, g/L | 30.0 (16.5–44.7) | 32.5 (17.1–47.2) | 0.001 |
| DDD | 116 (36–255) | 109 (0–300) | 0.013 |
mNGS, metagenomic next generation sequencing; NLR, neutrophil-to-lymphocyte ratio; Cre, creatinine; PLR, platelet-to-lymphocyte ratio; DDD, defined daily dose; PCT, procalcitonin; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
Data are presented as means (range).